Cargando…

The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey

BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Midilli, Kenan, Gargılı, Ayşen, Ergonul, Onder, Elevli, Murat, Ergin, Sevgi, Turan, Nesrin, Şengöz, Gönül, Ozturk, Recep, Bakar, Mehmet
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700115/
https://www.ncbi.nlm.nih.gov/pubmed/19515251
http://dx.doi.org/10.1186/1471-2334-9-90
_version_ 1782168578444754944
author Midilli, Kenan
Gargılı, Ayşen
Ergonul, Onder
Elevli, Murat
Ergin, Sevgi
Turan, Nesrin
Şengöz, Gönül
Ozturk, Recep
Bakar, Mehmet
author_facet Midilli, Kenan
Gargılı, Ayşen
Ergonul, Onder
Elevli, Murat
Ergin, Sevgi
Turan, Nesrin
Şengöz, Gönül
Ozturk, Recep
Bakar, Mehmet
author_sort Midilli, Kenan
collection PubMed
description BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed by RT-PCR and sequencing. A human serologic and tick survey studies were performed in the region, where the case detected. RESULTS: Thirty eight individuals out of 741 were found to be anti CCHFV IgM positive. The attack rate for overall CCHFV was calculated as 5.2%. In univariate analyses, CCHFV IgM positivity was found to be associated with the age (p < 0.001), male gender (p = 0.001), agricultural activity (p = 0.036), and history of tick bite (p = 0.014). In multivariate analysis, older age (OR: 1.03, CI:1.01–1.05, p < 0.001), male gender were found to be the risk factors (OR: 2.5, CI:1.15–5.63, p = 0.020) for CCHFV infection. CONCLUSION: This is the first human case with AP92 like CCHFV infection. Furthermore, this is the first report of AP92 like strain in Turkey. In the region, elderly males carry the highest risk for CCHFV infection.
format Text
id pubmed-2700115
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27001152009-06-23 The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey Midilli, Kenan Gargılı, Ayşen Ergonul, Onder Elevli, Murat Ergin, Sevgi Turan, Nesrin Şengöz, Gönül Ozturk, Recep Bakar, Mehmet BMC Infect Dis Research Article BACKGROUND: Crimean-Congo Hemorrhagic Fever (CCHF) is a fatal infection, but no clinical case due to AP92 strain was reported. We described the first clinical case due to AP92 like CCHFV. METHODS: A case infected by a AP92 like CCHFV was detected in Balkanian part of Turkey. Diagnosis was confirmed by RT-PCR and sequencing. A human serologic and tick survey studies were performed in the region, where the case detected. RESULTS: Thirty eight individuals out of 741 were found to be anti CCHFV IgM positive. The attack rate for overall CCHFV was calculated as 5.2%. In univariate analyses, CCHFV IgM positivity was found to be associated with the age (p < 0.001), male gender (p = 0.001), agricultural activity (p = 0.036), and history of tick bite (p = 0.014). In multivariate analysis, older age (OR: 1.03, CI:1.01–1.05, p < 0.001), male gender were found to be the risk factors (OR: 2.5, CI:1.15–5.63, p = 0.020) for CCHFV infection. CONCLUSION: This is the first human case with AP92 like CCHFV infection. Furthermore, this is the first report of AP92 like strain in Turkey. In the region, elderly males carry the highest risk for CCHFV infection. BioMed Central 2009-06-10 /pmc/articles/PMC2700115/ /pubmed/19515251 http://dx.doi.org/10.1186/1471-2334-9-90 Text en Copyright ©2009 Midilli et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Midilli, Kenan
Gargılı, Ayşen
Ergonul, Onder
Elevli, Murat
Ergin, Sevgi
Turan, Nesrin
Şengöz, Gönül
Ozturk, Recep
Bakar, Mehmet
The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title_full The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title_fullStr The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title_full_unstemmed The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title_short The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey
title_sort first clinical case due to ap92 like strain of crimean-congo hemorrhagic fever virus and a field survey
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700115/
https://www.ncbi.nlm.nih.gov/pubmed/19515251
http://dx.doi.org/10.1186/1471-2334-9-90
work_keys_str_mv AT midillikenan thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT gargılıaysen thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT ergonulonder thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT elevlimurat thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT erginsevgi thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT turannesrin thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT sengozgonul thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT ozturkrecep thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT bakarmehmet thefirstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT midillikenan firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT gargılıaysen firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT ergonulonder firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT elevlimurat firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT erginsevgi firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT turannesrin firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT sengozgonul firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT ozturkrecep firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey
AT bakarmehmet firstclinicalcaseduetoap92likestrainofcrimeancongohemorrhagicfevervirusandafieldsurvey